{"id":"randomisation-course-2-adxe-versus-fladx","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ADxE and FLADx are both involved in the regulation of the immune system. They work by targeting specific pathways to modulate immune responses. However, the exact mechanisms of action for ADxE and FLADx are not well understood.","oneSentence":"ADxE and FLADx are both involved in the regulation of the immune system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:21.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various autoimmune diseases"}]},"trialDetails":[{"nctId":"NCT01828489","phase":"PHASE3","title":"Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2013-03","conditions":"Pediatric Acute Myeloblastic Leukemia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Randomisation course 2 ADxE versus FLADx","genericName":"Randomisation course 2 ADxE versus FLADx","companyName":"Vastra Gotaland Region","companyId":"vastra-gotaland-region","modality":"Small molecule","firstApprovalDate":"","aiSummary":"In the NOPHO-DBH AML 2012 Protocol, a clinical trial was conducted to compare the effectiveness of two treatments for pediatric acute myeloblastic leukemia: Randomisation course 2 ADxE versus FLADx. The trial focused on the treatment of children and adolescents with acute myeloid leukemia aged 0-18 years.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}